Zimmer Biomet stock trades at EUR 94.74 late Thursday
Published on 11/13/2026 at 00:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBusiness and market position
- Zimmer Biomet develops orthopedic implants, surgical equipment and digital technologies for healthcare providers.
- The company serves the Americas, Europe, the Middle East, Africa and Asia Pacific.
- Morningstar identifies Stryker, Smith & Nephew and Johnson & Johnson as key competitors.
Zimmer Biomet stock traded at 94.74 euros on Lang & Schwarz at 11:00 p.m. CET on Thursday, November 12, 2026. The quote was 0.03 percent above the previous Lang & Schwarz close.
Orthopedic portfolio remains central
Zimmer Biomet describes itself as a medical technology company focused on orthopedic care. Its portfolio includes implants, digital technologies and robotic systems supporting hip, knee, shoulder, sports medicine and other procedures, according to the Zimmer Biomet website.
The company also highlights integrated technologies that connect surgical planning, robotics and patient care. That combination links its implant business with tools used by surgeons and healthcare providers, giving investors a business model that extends beyond individual devices.
Competition shapes the outlook
Zimmer Biomet operates in a concentrated medical-device field where product breadth, clinical evidence, surgeon relationships and hospital purchasing decisions influence growth. The company competes with Stryker, Smith & Nephew and Johnson & Johnson, according to Morningstar. Morningstar describes Zimmer Biomet as a market leader in large-joint reconstruction, while Stryker and other peers provide broad competing portfolios.
Company profile and positioning
Zimmer Biomet Holdings, Inc. designs, manufactures and markets orthopedic reconstructive implants and surgical equipment. Its main geographic segments are the Americas, Europe, the Middle East and Africa, and Asia Pacific, with headquarters in Warsaw, Indiana, United States. The company is a specialist in orthopedic reconstruction, while Stryker, Smith & Nephew and Johnson & Johnson compete across overlapping medical-device categories with broader or differently weighted portfolios. The competitive position therefore depends on maintaining surgeon adoption and expanding the use of connected technologies alongside implants.
Zimmer Biomet at a glance
- Company: Zimmer Biomet Holdings, Inc.
- ISIN: US98956P1021
- Ticker: ZBH
- Trading venue: Lang & Schwarz
- Quote: 94.74 euros at 11:00 p.m. CET on November 12, 2026
- Sector: Healthcare
- Industry: Medical Devices
- Headquarters: Warsaw, Indiana, United States
US equities remain part of the broader market setting tracked through the S&P 500.
More news and analyses on Zimmer Biomet stock.
